Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells - Wikidata - awgldk - TriplyDB

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

http://www.wikidata.org/entity/Q34605490

about

Tuberculosis vaccines: beyond bacille Calmette-Guerin Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera Recent advances in the development of vaccines for tuberculosis Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis Vaccines against tuberculosis: where are we and where do we need to go?Prime-boost approaches to tuberculosis vaccine development Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines Strategic Priming with Multiple Antigens can Yield Memory Cell Phenotypes Optimized for Infection with Mycobacterium tuberculosis: A Computational Study Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults Signatures of T cells as correlates of immunity to Francisella tularensis Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8(+) T cell responses.Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A Dual neonate vaccine platform against HIV-1 and M. tuberculosis.Identification of Mycobacterium tuberculosis-specific Th1, Th17 and Th22 cells using the expression of CD40L in tuberculous pleurisy.Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.Identification of M. tuberculosis-specific Th1 cells expressing CD69 generated in vivo in pleural fluid cells from patients with tuberculous pleurisy GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.Analysis of intracellular expressed proteins of Mycobacterium tuberculosis clinical isolates.Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice.Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)Vaccine against tuberculosis: what's new?Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.Vaccines and global health.Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses

P2860

Q22242669-827B21FB-B6A9-4802-8FDF-D0BD34EF932E Q24620207-7CB40E33-4537-4909-918E-EADA61F2D1B5 Q26796440-06D4FBCE-B036-48EE-B023-635736654038 Q26798372-898BD413-C244-4055-A9C9-DB8B82EF2EE6 Q26849399-DA87E25F-7C56-4EF7-82A0-36337D0B1AC5 Q26863391-64E8BEAC-87E5-4DFF-829D-75E31E62D11B Q26992233-92D7B0FA-A051-4587-8FFC-E17A980A1043 Q27024526-AAD34171-68A5-4A74-B51D-398C92EAAFEB Q27321593-491A9C0F-A249-4512-BB6F-741C965E543C Q28476626-D3C1CE69-0666-4F68-B91A-B43361B5C684 Q28603191-9CDB62C7-92AC-4A90-A65E-6CD467E699CB Q28728311-1DC50441-0A49-4672-B661-17AA104D069D Q28731483-DD763864-B5A0-4AE6-8485-997E59622F6E Q28740954-11F66E37-CA4C-487D-AA8C-D7E46575ACD3 Q28742450-EE831337-DA2E-4890-9ECF-A6378AF11153 Q29620144-4CD5424B-2547-4062-91C8-C7C525D96A85 Q33637297-4C8B3B3C-1A97-4D5E-8EFD-9065615E626B Q33770851-37194581-6245-48A1-B106-CE4D427AC0C4 Q33850516-A72A628F-8BA5-4214-9E18-0A74B97A4A45 Q33899366-26B8D0FC-C76C-44DC-8529-4BCF4D6C85F2 Q33908584-D12DC8DC-41C6-4EA9-A35F-E8827C468ED7 Q33916768-C0476246-CCAC-4E18-A86D-F4E3B42F67C4 Q33992101-FBFCD02E-0D53-4843-ABA9-A94A11CC3C5D Q34009517-3C4BFDE3-583E-4954-A711-11DD06EF33CA Q34023265-E617022D-15AE-4CDB-A9FA-CB7DD1FCB504 Q34055234-25FA2BBA-987F-4DC5-843A-59214493E262 Q34178610-4B26F2FA-F5B2-4283-AB41-B464F6113F9D Q34225046-FE54EEC9-BBBF-4403-944E-8D2F2FFDCC03 Q34566079-F08DBBB1-AB9C-47B9-84EA-5CDBA2E52A99 Q34663035-D4070DD6-637F-4FB3-997F-8773F67404C6 Q34985591-E5CC9369-8727-4502-951A-EBD836D26B5A Q35032532-6BB21298-8A55-44EF-B6B5-C2E4D7C4B884 Q35046608-9929C9D1-2DD5-40D1-9279-FBB897ECAB84 Q35053133-D21E9A06-5A8C-4303-9AA1-35E602905BFA Q35101472-0E9070DB-3E77-426D-93FF-C11B99FFE4FD Q35111389-31BC8BC8-4130-4120-BF29-625D99B253A7 Q35117812-2DACCB22-40A8-4C82-A4AA-E6660526C462 Q35137116-217DAD19-AC8B-400D-8674-ADF105F11260 Q35231023-5C0986D7-5BE4-4E1F-86E0-D0F171EB4685 Q35331449-59AC161A-1281-4C15-B3DC-3DA44272A297

P2860

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

http://www.wikidata.org/entity/Q34605490

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@ast

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@en

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@nl

type

label

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@ast

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@en

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@nl

prefLabel

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@ast

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@en

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@nl

P1433

Q34605490-D0FF6C97-0B70-417A-9403-E26689B397A7

P1476

Q34605490-CF2F8186-422C-4077-98E3-944851E820AE

P2093

Q34605490-0195E3B0-C3B9-40D2-9442-003AC9C38D18

Q34605490-02976DDF-D708-490A-80F6-0763A67E892D

Q34605490-115C61BC-978B-4019-8A66-A8ECC63D084D

Q34605490-1833C43F-C3AB-4BCD-BAA2-8F906ED98338

Q34605490-2D26CF3B-C07E-4541-AF38-1039D07E11F3

Q34605490-31E70891-B281-4728-9BD0-4AF0E965CB8B

Q34605490-99D37305-D8A1-418A-A8C8-4485EE18CE34

Q34605490-9D0AA70C-B12E-4E99-B38F-6A149BD65640

Q34605490-DD6C409A-3F75-4276-AA61-859A825E576E

Q34605490-E46703A8-0CEE-4098-985F-160758576580

P2860

Q34605490-02F0B681-C4DB-4CCA-AA47-94B780CD0232

Q34605490-07969857-B520-401A-80B2-09F89E0C8BC4

Q34605490-0AFFE286-0A3F-4C90-9255-5B732971C7F4

Q34605490-0B9E3A57-203F-4423-8B25-48E10DDC371F

Q34605490-0BDC94FB-E267-4FD4-BDA9-A454E92EA688

Q34605490-0CCF4DF4-BDF3-4835-99C6-F55E9A67E088

Q34605490-10EB2BA1-7133-4052-94B4-5ABC78AA683F

Q34605490-1B4F628D-6D7B-4937-8BC5-FFB965515433

Q34605490-1D3BA525-3015-4AB1-9D43-D7228F226B7D

Q34605490-1F80E6AC-FFD5-4B7E-94FA-A46168961A37

P304

Q34605490-67E54CB2-FAF1-4A7F-946D-867CAAD4DA2A

P31

Q34605490-AD565849-3BD9-4668-BC2D-DD6313A47ABA

P356

Q34605490-01465D63-E538-472A-BDB2-9F754490A8D5

P407

Q34605490-BF0D6339-3747-4170-BEE4-85F2125FAD6C

P433

Q34605490-8C70F04D-C15C-4184-9276-0B29276100DA

P478

Q34605490-BDD47260-7EE8-4357-8CC5-4CB706F80AD7

P50

Q34605490-3EBE436C-A3EB-497B-BE2B-8912149A269B

Q34605490-4E9DB223-2A4E-43EE-AC1E-F79CB0A272DC

Q34605490-5CC30FF8-5398-4B7E-9859-D424A757EB3E

Q34605490-78612B6F-9FE2-4939-BD8D-3CF0ECB22086

Q34605490-ADEB4A6F-9736-4055-81F9-7C3CE88733BF

Q34605490-B275C555-AA7B-4F58-ACB1-76CEF38E7527

Q34605490-D36F5CFB-5FF2-4449-9EEA-29D7AA1B99A9

P577

Q34605490-79E367FF-DD43-49CA-A94F-6CB60D10A996

P5875

Q34605490-5D263B10-3AC0-48A5-91EC-239EFAEE2C31

P698

Q34605490-3446CC19-6D12-4D51-8E3C-9F2F5B3E70C2

P921

Q34605490-384E39B8-A694-4C8A-B3BC-C138AAADAC4C

Q34605490-8A847886-7E90-4EE1-9FA0-A6BC140BA21E

P932

Q34605490-80488B81-49F3-466E-9E2D-B95F7108CA5D

P356

P1433

European Journal of Immunology

P1476

Modified vaccinia Ankara-expre ...... es polyfunctional CD4+ T cells

@en

P2093

Alana Keyser

http://www.w3.org/2001/XMLSchema#string

Alison Lawrie

http://www.w3.org/2001/XMLSchema#string

Anthony Hawkridge

http://www.w3.org/2001/XMLSchema#string

Ashley Veldsman

http://www.w3.org/2001/XMLSchema#string

Erica Smit

http://www.w3.org/2001/XMLSchema#string

Fatima Isaacs

http://www.w3.org/2001/XMLSchema#string

Hassan Mahomed

http://www.w3.org/2001/XMLSchema#string

Linda van der Merwe

http://www.w3.org/2001/XMLSchema#string

Nathaniel Brittain

http://www.w3.org/2001/XMLSchema#string

Nazma Mansoor

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

Phenotypic and functional features of human Th17 cells

P304

279-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJI.200939754

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Adrian V. S. Hill

Michele Tameris

Willem Albert Hanekom

Thomas J Scriba

Gregory D Hussey

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40694565

http://www.w3.org/2001/XMLSchema#string

P698

20017188

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3044835

http://www.w3.org/2001/XMLSchema#string